Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,506.48
(
-1.51%
)
US TECH 100
23,484.80
(
-0.99%
)
Dow Jones
45,577.47
(
-0.96%
)
Brent Oil
106.93
(
0.00%
)
Bitcoin
70,645.99
(
0.18%
)
News Focus
News Focus
Post# of 257266
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122806
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: mcbio post# 100063

Wednesday, 07/28/2010 11:25:09 PM

Wednesday, July 28, 2010 11:25:09 PM

Post# of 257266

VRUS appears to be making a big deal about PSI-938 being potent against the 'S282T mutant' (#msg-52714527).

I don’t award PSI-938—or any other HCV drug—extra brownie points for these kinds of attributes. All HCV drugs in development today are intended to be part of 2- or 3-drug combinations where the cocktail components have complementary resistance profiles. So I don’t think there’s a lot of investment value in focusing on specific mutations such as S282T.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today